Interestingly, RET/Src signaling showed no influence on MHC-I levels, while suppression of RET/Src signaling by regorafenib reduced IFN-γ-induced expression of PD-L1 and IDO1 on tumor cells. This evidence concerns the gene RET and neoplasm.